Wall Street brokerages expect Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) to post earnings of $0.97 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Valeant Pharmaceuticals Intl’s earnings, with the lowest EPS estimate coming in at $0.81 and the highest estimate coming in at $1.29. Valeant Pharmaceuticals Intl reported earnings of $1.26 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 23%. The firm is scheduled to report its next earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Valeant Pharmaceuticals Intl will report full year earnings of $3.82 per share for the current year, with EPS estimates ranging from $3.61 to $4.15. For the next financial year, analysts anticipate that the business will report earnings of $3.44 per share, with EPS estimates ranging from $2.96 to $4.11. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Valeant Pharmaceuticals Intl.
A number of analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a report on Saturday. TD Securities lifted their price target on shares of Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the company a “buy” rating in a report on Friday, January 5th. Wells Fargo & Co reiterated a “sell” rating on shares of Valeant Pharmaceuticals Intl in a report on Thursday, January 4th. JPMorgan Chase & Co. downgraded shares of Valeant Pharmaceuticals Intl from a “neutral” rating to an “underweight” rating and set a $12.00 price target on the stock. in a report on Thursday, December 14th. Finally, ValuEngine upgraded shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a report on Tuesday, December 12th. Six analysts have rated the stock with a sell rating, ten have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals Intl has a consensus rating of “Hold” and an average price target of $18.20.
In other Valeant Pharmaceuticals Intl news, Director John Paulson bought 344,216 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Thursday, November 16th. The shares were purchased at an average cost of $14.40 per share, for a total transaction of $4,956,710.40. Following the acquisition, the director now directly owns 94,559 shares in the company, valued at approximately $1,361,649.60. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.87% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Riggs Asset Managment Co. Inc. increased its holdings in shares of Valeant Pharmaceuticals Intl by 118.2% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 4,512 shares during the last quarter. Cetera Investment Advisers purchased a new position in shares of Valeant Pharmaceuticals Intl during the 2nd quarter worth about $192,000. Harbour Capital Advisors LLC purchased a new position in shares of Valeant Pharmaceuticals Intl during the 3rd quarter worth about $224,000. American Century Companies Inc. purchased a new position in shares of Valeant Pharmaceuticals Intl during the 3rd quarter worth about $238,000. Finally, Moors & Cabot Inc. boosted its stake in shares of Valeant Pharmaceuticals Intl by 32.3% during the 2nd quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after purchasing an additional 3,725 shares during the period. Hedge funds and other institutional investors own 49.45% of the company’s stock.
Shares of Valeant Pharmaceuticals Intl (VRX) traded up $0.03 during midday trading on Friday, reaching $23.84. 10,210,000 shares of the company’s stock were exchanged, compared to its average volume of 20,720,000. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. The company has a market cap of $8,300.00, a P/E ratio of 6.11, a P/E/G ratio of 0.72 and a beta of -0.22. Valeant Pharmaceuticals Intl has a one year low of $8.31 and a one year high of $24.43.
TRADEMARK VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/0-97-eps-expected-for-valeant-pharmaceuticals-intl-inc-vrx-this-quarter.html.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Get a free copy of the Zacks research report on Valeant Pharmaceuticals Intl (VRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.